Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.43 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 4/20 | 0.41 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.38 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.38 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.37 |
| ▸ | MC1R | Q01726 | 7/20 | 0.48 |
| ▸ | MC4R | P32245 | 6/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
| ▸ | AKT2 | P31751 | 2/20 | 0.47 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.47 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14360370 | 1.00 | MC1R (0.48) | MC1RMC4RAKT1AKT2AKT3 | |
| Hydrochloric Acid SCHEMBL1310496 | 0.86 | MC1R (0.60) | MC1RMC4RAKT1AKT2AKT3 | |
| Hydrochloric Acid SCHEMBL1310494 | 0.86 | MC1R (0.60) | MC1RMC4RAKT1AKT2AKT3 | |
| SCHEMBL14360597 | 0.86 | MC1R (0.58) | MC1RMC4RGRIN2B | |
| SCHEMBL1310763 | 0.84 | MC1R (0.48) | MC1RMC4RAKT1AKT2AKT3 | |
| SCHEMBL1310765 | 0.84 | MC1R (0.48) | MC1RMC4RAKT1AKT2AKT3 | |
| Trifluoroacetic Acid SCHEMBL14360092 | 0.81 | MC1R (0.48) | MC1RMC4RAKT1AKT2AKT3 | |
| Trifluoroacetic Acid SCHEMBL1310217 | 0.81 | MC1R (0.57) | MC1RMC4RAKT1AKT2AKT3 | |
| Trifluoroacetic Acid SCHEMBL1312510 | 0.79 | MC1R (0.55) | MC1RMC4RAKT1AKT2AKT3 | |
| SCHEMBL2154187 | 0.79 | MC1R (0.52) | MC1RMC4RHDAC8OPRK1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981952-B2 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-05-29 | — | — | US | disclosed |
| EP-2726478-B1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2017-01-11 | — | — | EP | disclosed |
| US-20160237065-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-18 | — | — | US | disclosed |
| US-9353083-B2 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-05-31 | — | — | US | disclosed |
| US-20140228342-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-14 | — | — | US | disclosed |
| EP-2726478-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013001030-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237065-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | MC1R, MCHR1, MCHR2 | DPP4 4650/4885HDAC8 1539/4885GRIN2B 737/4885 |
| US-20140228342-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | MC1R, MCHR1, MCHR2 | DPP4 4502/4885HDAC8 1248/4885GRIN2B 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.